Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells

Yamazaki, Hiroto; Naito, Motohiko; Ghani, Farhana Ishrat; Dang, Nam H.; Iwata, Satoshi; Morimoto, Chikao

doi:10.1016/j.bbrc.2012.02.054

Cited by 29 publications

(39 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study demonstrated that CSCs CD26 + of MM (JMN cell line) is resistant to treatment with daunomycin [32]. Interestingly, the treatment of colorectal CSC with oxaliplatin showed similar results in animals by selecting CSC CD133 + /CD26 + , where the treatment maintained tumor volume, but the percentage of CD133 + /CD26 + cells at the tumor almost quadrupled.…”

Section: Resultsmentioning

confidence: 62%

See 1 more Smart Citation

CD26 a cancer stem cell marker and therapeutic target

Davies

Beckenkamp

Buffon

2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 62%

“…So, it is suggested that CD26 is closely linked to the maintenance of CSC growth. It was also demonstrated that this protein promotes a more invasive behavior of CSC, which however was significantly decreased when CD26 expression was silenced in Meso-1 cell line [32]. The invasiveness of CD26 + cells was further analyzed in MM.…”

Section: Resultsmentioning

confidence: 98%

CD26 a cancer stem cell marker and therapeutic target

Davies

Beckenkamp

Buffon

2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…CSCs are thought to play an integral role in metastasis and recurrence following chemotherapy (17). Although several putative CSC markers have been proposed in MPM (18, 19), they have not been rigorously validated. ALDH activity has been used to define CSCs in numerous solid tumor types (17).…”

Section: Discussionmentioning

confidence: 99%

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

et al. 2014

View full text Add to dashboard Cite

The goal of targeted therapy is to match a selective drug with a genetic lesion that predicts for drug sensitivity. In a diverse panel of cancer cell lines, we found that the cells most sensitive to focal adhesion kinase (FAK) inhibition are deficient in the expression of the NF2 tumor suppressor gene product, Merlin. Merlin expression is often lost in malignant pleural mesothelioma (MPM), an asbestos-induced aggressive cancer with limited treatment options. Our data demonstrate that low Merlin expression predicts for increased sensitivity of MPM cells to a FAK inhibitor, VS-4718, in vitro and in tumor xenograft models. Disruption of MPM cell-cell or cell-extracellular matrix (ECM) contacts with blocking antibodies suggests that weak cell-cell adhesions in Merlin-negative MPM cells lead to their greater dependence on cell-ECM-induced FAK signaling. This provides one explanation of why Merlin-negative cells are vulnerable to FAK inhibitor treatment. Furthermore, we validated ALDH as a marker of cancer stem cells (CSCs) in MPM, a cell population thought to mediate tumor relapse after chemotherapy. Whereas pemetrexed and cisplatin, standard-of-care agents for MPM, enrich for CSCs, FAK inhibitor treatment preferentially eliminates these cells. These preclinical results provide the rationale for a clinical trial in MPM patients using a FAK inhibitor as a single agent after first-line chemotherapy. With this design, the FAK inhibitor could potentially induce a more durable clinical response due to reduction of CSCs along with a strong antitumor effect. Furthermore, our data suggest that patients with Merlin-negative tumors may especially benefit from FAK inhibitor treatment.

show abstract

“…They did not detect the expression of CD133 (a pluripotent stem cell marker) as well as CD31 or CD144 (endothelial stem cell markers) in MM CSC. Another study examined CSC in three MM cell lines and the authors concluded that CD24-and CD26-positive MM cells have stem cell-like properties as they showed asymmetric cell division, higher proliferative potential, and chemoresistance [132]. Cortes-Dericks et al reported that the expressions of several putative cancer stem cell markers, CD133, Bmi-1, uPAR, and ABCG2 are associated with chemoresistance of MPM cells.…”

Section: Cancer Stem(-like) Cells (Csc) In MMmentioning

confidence: 98%